Abstract:BACKGROUND: Low grade glioma is one of the most common lethal cancers in the human nervous system. Emerging evidence has demonstrated that homeobox A cluster (HOXA) gene family plays a critical role in the transcriptional regulation as well as cancer initiation and progression. However, the expression, biological functions and upstream regulatory mechanism of 11 HOXAs in low grade glioma are not yet clear.METHODS: In this study, we utilized various public databases and bioinformatics analyzed, including TCGA, CGGA, Rembrandt, HPA, LinkedOmics, cBioPortal, TISDIB, single-sample GSEA (ssGSEA), TIMER, LnCeVar, LASSO regression, Cox regression, Kaplan-Meier plot, and receiver operating, characteristic (ROC) analyses, GDSC and CTRP databases to analyzed the mRNA and protein expression profiles, gene mutation, clinical features, diagnosis, prognosis, signaling pathway, TMB, immune subtype, immune cell infiltration, immune modulator, ceRNA network and drug sensitivity of 11 HOXAs. Growth curve and transwell assays were utilized to study the biological characteristics of HOXA6 in LGG progression.RESULTS: In the present study, we found that 11 HOXAs (HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, HOXA10, HOXA11 and HOXA3) were consistently up-regulated in LGG tissues and GBM tissues. Up-regulated of the HOXAs expression were significantly correlated with higher tumor stage, IDH mutation status, 1p/19q co-deletion, histological type and primary therapy outcome. Survival analyses showed that higher expression of HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, HOXA7, HOXA9, HOXA10, HOXA11 and HOXA13 were correlated with shorter overall survival (OS), disease-specific survival (DSS) and progression-free survival (PFS) in LGG patients. Univariate and multivariate analyses revealed that HOXA1, HOXA6 expression and tumor grade, age, primary therapy outcome and age were independent factors affecting the prognosis of LGG patients. ROC curve analysis of HOXAs showed that HOXAs had a high accuracy (AUC > 0.80) in predicting LGG. Furthermore, gene functional enrichment analysis indicated that HOXAs mainly involved in the inflammatory response and immune regulation signaling pathway. CNV and DNA methylation significantly affect the expression of HOXAs. Finally, we uncover that HOXAs expression are highly correlated with immune cells infiltrate, immune modulator and drug sensitivity. We also uncover that the HOXAs related ceRNA network in LGG. More importantly, we found that HOXA6 was highly expressed in LGG cells lines and significantly affected their proliferation and migration abilities.CONCLUSIONS: In conclusion, our data demonstrated that HOXA was correlated with progression and immune infiltration, and could serve as a prognostic biomarker for LGG.

The Expression of Long Non-coding RNA HOXA11-AS and Its Clinical Significance in Glioma

Knockdown of Lncrna HOXD-AS2 Improves the Prognosis of Glioma Patients by Inhibiting the Proliferation and Migration of Glioma Cells

The expression of long non-coding RNA XIST in glioma and its clinical significance

Expression level and clinical significance of long non-coding RNA SNHG3 in glioma

Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients

Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma

A Novel Cell Cycle-Associated Incrna, Hoxa11-As, Is Transcribed From The 5-Prime End Of The Hoxa Transcript And Is A Biomarker Of Progression In Glioma

Abnormal expression of HOXD11 promotes the malignant behavior of glioma cells and leads to poor prognosis of glioma patients

Long non-coding RNA HOXA-AS2 may serve as a new therapeutic target and promising prognostic market for most of cancers

Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma

LncRNA HOXA11-AS promotes glioma malignant phenotypes and reduces its sensitivity to ROS via Tpl2-MEK1/2-ERK1/2 pathway

A Meta-Analysis of the Prognostic Value of Abnormally Expressed Lncrnas and Correlation with Clinicopathological Characteristics in Glioma

Expression and Clinicopathological Significance of the Lncrna HOXA11-AS in Colorectal Cancer.

Expression and Clinical Significance of Long Non-Coding RNA-CAI2 in Glioma

Upregulation of the Long Non-Coding RNA SNHG1 Predicts Poor Prognosis, Promotes Cell Proliferation and Invasion, and Reduces Apoptosis in Glioma.

Analysis of Long Noncoding RNA ZNF667-AS1 as a Potential Biomarker for Diagnosis and Prognosis of Glioma Patients

Prediction of relapse and prognosis by expression levels of long noncoding RNA PEG10 in glioma patients

Long Non-Coding RNA HOXA11-AS in Human Cancer: A Meta-Analysis.

Expression of TXLNA in brain gliomas and its clinical significance: a bioinformatics analysis

Prognostic and clinicopathological significance of long non-coding RNA in glioma

HOXA-AS2 may predict the prognosis of solid tumors among Chinese patients: A meta-analysis and bioinformatic analysis